Clinical trials: Prostate Adenocarcinoma
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
LHRH Analogue Therapy With Enzalutamide or Bicalutamide in Treating Patients With Hormone Sensitive Prostate Cancer
This randomized phase II trial studies if enzalutamide added to standard luteinizing hormone-releasing hormone (LHRH) analogue therapy will improve effects against prostate cancer compared to the standard therapy of LHRH analogue…
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer
- Trial name
- NCT02058706
- Testing
- enzalutamide, bicalutamide, orchiectomy
- Where
- 4 sites in United States
- Volunteers
- 71 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Prostate Cancer
Ultrasound-Guided Implant Radiation Therapy in Treating Patients With Locally Recurrent Prostate Cancer Previously Treated With External-Beam Radiation Therapy
RATIONALE: Implant radiation therapy uses radioactive material placed directly into or near a tumor to kill tumor cells. PURPOSE: This phase II trial is studying the side effects and how well ultrasound-guided implant radiation…
- Trial name
- NCT00450411
- Testing
- 125-Iodine, 103-palladium
- Where
- 17 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer, Adenocarcinoma of the Prostate
Taxotere/Prednisone Plus Sunitinib in Chemotherapy-Naïve, Hormone Refractory Prostate Cancer Patients
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Prostate Cancer, Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer
- Trial name
- NCT00879619
- Testing
- sunitinib malate, docetaxel, prednisone
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- John P. Fruehauf
Metastatic Cancer, Prostate Cancer
Paricalcitol in Treating Patients With Advanced Prostate Cancer and Bone Metastases
RATIONALE: Paricalcitol may help prostate cancer cells become more like normal cells, and to grow and spread more slowly. It may also stop the growth of tumor cells in bone.
- Trial name
- NCT00634582
- Testing
- paricalcitol, immunoenzyme technique, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Wake Forest University Health Sciences
Prostate Cancer
Interstitial Brachytherapy With or Without External-Beam Radiation Therapy in Treating Patients With Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays and other sources to damage tumor cells. Interstitial brachytherapy uses radioactive material placed directly into or near a tumor to kill tumor cells.
- Trial name
- NCT00063882
- Testing
- Brachytherapy (100/110), Brachytherapy (125/145), External Beam Radiation Therapy
- Where
- 170 sites in United States, Canada
- Volunteers
- 588 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Adenocarcinoma
Apalutamide in Treating Patients With Prostate Cancer Who Are in Active Surveillance
This phase II trial studies how well apalutamide works in treating patients with prostate cancer who are in active surveillance. Testosterone can cause the growth of prostate cancer cells.
- Trial name
- NCT02721979
- Testing
- Apalutamide, Laboratory Biomarker Analysis, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- University of Washington
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Cinacalcet Hydrochloride in Treating Men With Recurrent Prostate Cancer
This phase II trial is studying how well cinacalcet hydrochloride works in treating men with recurrent prostate cancer. Cinacalcet hydrochloride may be effective in lowering prostate-specific antigen (PSA) levels in patients with…
- Trial name
- NCT01054079
- Testing
- laboratory biomarker analysis, quality-of-life assessment, questionnaire administration
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer
This phase II trial studies how well testosterone (enanthate or cypionate) and olaparib work in treating patients with prostate cancer that has progressed despite hormonal therapy.
- Trial name
- NCT03516812
- Testing
- Laboratory Biomarker Analysis, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Washington
Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
This phase II trial studies how well durvalumab and olaparib work in treating prostate cancer in men predicted to have specific genetic mutations (a high neoantigen load).
- Trial name
- NCT04336943
- Testing
- Durvalumab, Olaparib, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Washington
Prostate Cancer
Lapatinib in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Lapatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well lapatinib works in treating patients with prostate cancer that did…
- Trial name
- NRR (NCT00246753)
- Testing
- lapatinib ditosylate
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Adenocarcinoma of the Prostate
Enzalutamide in Patients With High-risk Prostate Cancer
The purpose of this study is to see how long it takes for prostate cancer to come back in patients who have had surgery to remove their prostate gland (radical prostatectomy), while being treated with enzalutamide (formerly known…
- Trial name
- NCT01927627
- Testing
- enzalutamide
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Case Comprehensive Cancer Center
Adenocarcinoma of the Prostate
Pilot Study of 18F-DCFPyL PET/CT in the Evaluation of Men With an Elevated PSA Following Radical Prostatectomy
This pilot study aims to investigate the diagnostic utility of 18F-DCFPyL, a novel low-molecular weight PSMA PET/CT imaging agent, in men with an elevated PSA following radical prostatectomy.
- Trial name
- NCT02523924
- Testing
- 18F-DCFPyL
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Neoplasms, Prostate Neoplasms
PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors
A Phase 1 dose escalation and expansion study evaluating safety, tolerability and pharmacokinetics of PF-06952229 in adult patients with advanced solid tumors.
- Conditions
- Breast Neoplasms, Prostate Neoplasms, Neoplasms, Squamous Cell, Melanoma
- Trial name
- NCT03685591
- Testing
- PF-06952229, Enzalutamide
- Where
- 15 sites in United States
- Volunteers
- 49 people
- Sponsor
- Pfizer
Prostate Cancer
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied.
- Trial name
- NCT01630590
- Testing
- Cabozantinib, Androgen Ablation Therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer, Adenocarcinoma of the Prostate
Intraoperative Dosimetry for Prostate Brachytherapy Using Fluoroscopy and Ultrasound
The purpose of this study is to assess the performance of a system of intraoperative dynamic dosimetry during prostate seed implantation (brachytherapy) including its new elements, to evaluate and refine technical methods of…
- Trial name
- NCT02225925
- Testing
- Brachytherapy
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
This partially randomized phase I/II trial studies cabazitaxel with or without carboplatin in treating patients with previously treated prostate cancer that has spread to other areas of the body and does not respond to treatment…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Lymphadenopathy, Metastatic Prostate Carcinoma
- Trial name
- NCT01505868
- Testing
- Cabazitaxel, Carboplatin, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 170 people
- Sponsor
- M.D. Anderson Cancer Center
Metastatic Prostate Cancer, Prostate Adenocarcinoma
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This is a Phase 3, multi-center, randomized, open-label, controlled study designed to evaluate the safety and efficacy of cabozantinib given in combination with atezolizumab versus a second novel hormonal therapy (NHT) in men…
- Trial name
- CONTACT-02 (NCT04446117)
- Testing
- Cabozantinib, Atezolizumab, Abiraterone Acetate
- Where
- 280 sites in United States, Argentina and 25 more
- Volunteers
- 575 people
- Sponsor
- Exelixis
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer
This phase II trial studies how well apalutamide and gonadotropin-releasing hormone analog with or without abiraterone acetate work in treating participants with prostate cancer prior to surgery.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8
- Trial name
- NCT03279250
- Testing
- Abiraterone Acetate, Apalutamide, Gonadotropin-releasing Hormone Analog
- Where
- United States
- Volunteers
- 86 people
- Sponsor
- M.D. Anderson Cancer Center
Adenocarcinoma of the Prostate, Recurrent Prostate Cancer
Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy
This pilot phase II trial studies how well giving bevacizumab works in treating patients with relapsed prostate cancer that did not respond to hormone therapy.
- Conditions
- Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer
- Trial name
- NCT01656304
- Testing
- bevacizumab, laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Small Cell Lung Cancer, Gastric Adenocarcinoma
PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies
The purpose of this signal seeking study is to determine whether treatment with PDR001 and LAG525 demonstrates sufficient efficacy in advanced malignancies to warrant further study.
- Conditions
- Small Cell Lung Cancer, Gastric Adenocarcinoma, Esophageal Adenocarcinoma, Castration Resistant Prostate Adenocarcinoma
- Trial name
- NCT03365791
- Testing
- PDR001, LAG525
- Where
- 20 sites in United States
- Volunteers
- 76 people
- Sponsor
- Novartis Pharmaceuticals